Serena Pezzilli

Serena Pezzilli

Auto-generated profile, based on publicly available information

Serena Pezzilli

Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2019 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
HDHamza Dallali
Hamza Dallali
SPSerena Pezzilli
Serena Pezzilli
MHMeriem Hechmi
Meriem Hechmi
OSOm Kalthoum Sallem
Om Kalthoum Sallem
SESahar Elouej
Sahar Elouej
RKRym KEFI
Rym KEFI

9 October 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
SPSerena Pezzilli
Serena Pezzilli
OLOrnella Ludovico
Ornella Ludovico
TBTommaso Biagini
Tommaso Biagini
LMLuana Mercuri
Luana Mercuri
FAFederica Alberico
Federica Alberico
SPSabrina Prudente
Sabrina Prudente
Multigenerational diabetes of adulthood is a mostly overlooked entity, simplistically lumped into the large pool of type 2 diabetes. The general aim of our research in the past few years is to unravel the genetic causes of this form of diabetes. Identifying among families with multigenerational diabetes those who carry mutations in known monogenic diabetes genes is the first step to then allow us to concentrate on remaining pedigrees in which to unravel new diabetes genes. Targeted next-generation sequencing of 27 monogenic diabetes genes was carried out in 55 family probands and identified mutations verified among their relatives by Sanger sequencing. Nine variants (in eight probands) survived our filtering/prioritization strategy. After likelihood of causality assessment by established guidelines, six variants were classified as “pathogenetic/likely pathogenetic” and two as “of uncertain significance.” Combining present results with our previous data on the six genes causing the most common forms of maturity-onset diabetes of the young allows us to infer that 23.6% of families with multigenerational diabetes of adulthood carry mutations in known monogenic diabetes genes. Our findings indicate that the genetic background of hyperglycemia is unrecognized in the vast majority of families with multigenerational diabetes of adulthood. These families now become the object of further research aimed at unraveling new diabetes genes.

22 July 2016 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
SPSabrina Prudente
Sabrina Prudente
RPRosa Di Paola
Rosa Di Paola
MCMassimiliano Copetti
Massimiliano Copetti
DLDaniela Lucchesi
Daniela Lucchesi
OLOlga Lamacchia
Olga Lamacchia
VTVincenzo Trischitta
Vincenzo Trischitta
Background UMOD variability has been associated at a genome-wide level of statistical significance with glomerular filtration rate (GFR) in Swedish individuals with type 2 diabetes (T2D; n = 4888). Whether this finding is extensible also to diabetic patients from other populations deserves further study. Our aim was to investigate the relationship between UMOD variability and GFR in patients with T2D from Italy. Methods Genotyping of the single nucleotide polymorphism (SNP) rs12917707 at the UMOD locus has been carried out in 3087 individuals from four independent Italian cohorts of patients with T2D by TaqMan allele discrimination. Results In none of the four study cohorts was rs12917707 significantly associated with GFR (P > 0.05 for all). Similar results were obtained when the four samples were pooled and analyzed together (β = 0.83, P = 0.19). Such effect was strikingly smaller than that previously reported in Swedish patients (P for heterogeneity = 1.21 × 10−7). Conclusions The previously reported strong association between rs12917707 and GFR in diabetic patients from Sweden is not observed in Italian diabetic patients, thus clearly pointing to a heterogeneous effect across the two different samples. This suggests that UMOD is a strong genetic determinant of kidney function in patients with T2D in some, but not all, populations.

11 July 2017 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
SPSabrina Prudente
Sabrina Prudente
RPRosa Di Paola
Rosa Di Paola
SPS Pezzilli
S Pezzilli
MGM Garofolo
M Garofolo
OLO Lamacchia
O Lamacchia
VTVincenzo Trischitta
Vincenzo Trischitta

13 August 2019 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
GMGaia Chiara Mannino
Gaia Chiara Mannino
SPSerena Pezzilli
Serena Pezzilli
CACarolina Averta
Carolina Averta
AFAnastasia Fuoco
Anastasia Fuoco
RSRosangela Spiga
Rosangela Spiga
GSGiorgio Sesti
Giorgio Sesti
Myocardial infarction is the main mortality cause in patients with type 2 diabetes (T2DM). Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step of atherogenesis. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, and it is metabolized by the enzymes dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2. The functional variant rs9267551 C, in the promoter region of DDAH2, has been linked to increased DDAH2 expression, and lower ADMA plasma levels, and was associated with lower risk of coronary artery disease in large-scale genome-wide association studies (GWAS) performed in the general population. However, it is unknown whether this association holds true in T2DM patients. To address this issue, we investigated whether rs9267551 is associated with risk of myocardial infarction in two cohorts of T2DM patients. SNP rs9267551 was genotyped in 1839 White T2DM patients from the Catanzaro Study (CZ, n = 1060) and the Gargano Heart Study-cross sectional design (GHS, n = 779). Cases were patients with a previous myocardial infarction, controls were asymptomatic patients with neither previous myocardial ischemia nor signs of it at resting and during a maximal symptom limited stress electrocardiogram. Carriers of allele rs9267551 C showed a dose dependent reduction in the risk of myocardial infarction [(CZ = OR 0.380, 95% CI 0.175–0.823, p = 0.014), (GHS = 0.497, 0.267–0.923, p = 0.027), (Pooled = 0.458, 0.283–0.739, p = 0.001)] which remained significant after adjusting for sex, age, BMI, smoking, HbA1c, total cholesterol HDL, and triglyceride levels [(CZ = 0.307, 0.106–0.885, p = 0.029), (GHS = 0.512, 0.270–0.970, p = 0.040), (Pooled = 0.458, 0.266–0.787, p = 0.005)]. We found that rs9267551 polymorphism is significantly associated with myocardial infarction in T2DM patients of European ancestry from two independent cohorts. It is possible that in subjects carrying the protective C allele less ADMA accumulates in endothelial cells causing vascular protection as a consequence of higher nitric oxide availability.